Eli Lilly and Company Reports Strong Q4 2025 Financial Results and 2026 Guidance
Summary
Eli Lilly and Company reported robust Q4 2025 financial results on February 4, 2026, via its Exhibit 99.1 press release, announcing significant growth driven by key products. Revenue surged 43% to $19.3 billion, primarily from Mounjaro and Zepbound volume. Reported EPS increased 51% to $7.39, with non-GAAP EPS up 42% to $7.54, both inclusive of $0.52 of acquired IPR&D charges. The company also provided 2026 guidance. * FDA approved Kwikpen for tirzepatide and expanded Jaypirca's indication. * Submissions for orforglipron for obesity in the U.S., Japan, and EU. * Positive Phase 3 results for Taltz and Zepbound, orforglipron, and retatrutide. * Agreement with U.S. government to expand obesity medicine access.
Why It Matters
The substantial Q4 2025 revenue and EPS growth, fueled by strong demand for Mounjaro and Zepbound, alongside positive regulatory approvals and pipeline advancements, signals robust operational performance and future growth prospects for investors. The company also provided 2026 guidance.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how LLY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View LLY Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000059478
- Filing Date
- Wednesday, February 4, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive